LIF Invite all interested to Open Health economic Method Seminar

Theme: How to evaluate new oncology treatments

22 March 2019 | Svea Konferens & Matsalar, Holländargatan 10 | Stockholm

Due to different regulatory initiatives more oncology products are introduced earlier in the development process. Health economic evaluations based on e.g. one-armed Phase 1 and 2 clinical trials requires further innovation and development of health economic methods. The main issue discussed in this seminar is how to handle 'uncertainty' due to lack of long-term data at launch. Especially methods of extrapolation beyond trial as well as interpretations of sensitivity analyses will be discussed.

Moderator: Mats Ekelund, Director Market Access, BiogenIdec

Lecture (13.00-13.40)

Ways of estimating overall survival, attributable to treatment, in oncology

Alastair Fischer, Senior Visiting Fellow at OHE, London with past experience from NICE

Reimbursement authorities for pharmaceutical products have made one of the main outcomes for cancer patients the extension in life expectancy or overall survival due to treatment. This is problematic in that OS is never measured with complete accuracy until everyone in the treatment arm of a trial has died. At the end of a trial, even extremely promising treatments might not be approved straight away because not enough time has elapsed (that is, not enough people have died) to determine OS with sufficient accuracy.

I expect to look at

- various forms of extrapolation of Kaplan-Meyer curves (including the use of hazard ratios between the arms of the trial)
- the use of surrogate endpoints such as progression-free survival
- the use of median survival times and thinking of the decision problem as predominantly an economic problem

I will also talk about

- distinguishing between delays in approval
- the price received by the manufacturer of a drug
- the value to patients who get the drug earlier rather than later"

Panel (13.40-14.20)

The lecture will be discussed by:

Andrea Berardi, Principal Consultant Parexel, MSc in Biostatistics with a focus on Bayesian methods in health economics

Martin Henriksson, Associate Professor Linköping University, member of the TLV Board

Comments from Industry (14.20-14.40)

Mattias Ekman, Health Economist, AstraZeneca Nordic & Baltic

Olof Lindgren, Market Access Mgr / Health Economist, Takeda

Kasper Johannesen, Health Economist, BMS Nordics

Comments from TLV (14.40-15.00)

Douglas Lundin, Chief Health Economist, Dental and Pharmaceutical Benefits Agency

Further networking and coffee

Registration

Please fill in registration form no later than19 March:

https://www.lyyti.fi/reg/Open_Health_economic_Method_Seminar_8309

LIF – de forskande läkemedelsföretagen